Complement Levels in Thrombotic Thrombocytopenic Purpura
In TTP, serum complement levels (C3 and C4) are typically normal, as TTP is not a complement-mediated thrombotic microangiopathy. This distinguishes TTP from other TMAs where complement activation plays a central pathogenic role.
Key Diagnostic Distinction
The complement system is not part of the core pathophysiology of TTP. The disease mechanism centers on ADAMTS13 deficiency (activity <10%) leading to accumulation of ultra-large von Willebrand factor multimers, not complement activation 1. This is a critical differentiating feature when evaluating patients with suspected thrombotic microangiopathy.
What the Guidelines Emphasize
The most recent 2025 ISTH guidelines 1 and 2025 expert reviews 2 make no mention of complement testing in the diagnostic workup or monitoring of TTP. The diagnostic focus is entirely on:
- ADAMTS13 activity <10% (mandatory for diagnosis)
- Anti-ADAMTS13 antibodies (to differentiate iTTP from cTTP)
- Evidence of microangiopathic hemolytic anemia
- Thrombocytopenia (usually <30 × 10⁹/L)
- Organ damage assessment
When Complement Testing Matters
Complement levels become relevant when ruling out other TMAs that can mimic TTP 2:
- Complement-mediated HUS (aHUS): Shows complement consumption with low C3, low C4, or both
- Secondary TMAs: May show variable complement patterns depending on underlying cause
- Pregnancy-associated TMAs: Complement testing helps differentiate between TTP and complement-mediated HUS
Research Evidence on Complement in TTP
While older case reports 3, 4 and recent COVID-19 studies 5 have documented complement deposition or consumption in isolated TTP cases, these represent exceptional findings, not the typical pattern. One study found that PTX3 elevation was associated with complement consumption in STEC-HUS, aHUS, and secondary TMA, but PTX3 elevation was exceptional in TTP 6.
Clinical Implication
If you find low C3 or C4 levels in a patient with suspected TTP, strongly reconsider the diagnosis. This pattern suggests:
- Complement-mediated HUS (aHUS)
- Secondary TMA with complement activation
- A different diagnosis entirely
The presence of complement consumption should prompt genetic testing for complement regulatory protein mutations and evaluation for alternative TMA etiologies before finalizing a TTP diagnosis.
Practical Algorithm
When evaluating thrombocytopenia with microangiopathic hemolytic anemia:
Send ADAMTS13 activity immediately (diagnostic gold standard)
Check complement levels (C3, C4, CH50) as part of TMA differential
Interpret results:
- Normal complements + ADAMTS13 <10% = TTP
- Low complements + normal/high ADAMTS13 = Consider aHUS or other complement-mediated TMA
- Normal complements + normal ADAMTS13 = Look for secondary causes
Start empiric treatment for TTP if clinical suspicion is high (don't wait for ADAMTS13 results) 2, 7